Novartis To Pay $245 Million To End Antitrust Cases Over Exforge Drug Generics
By Jonathan Stempel NEW YORK (Reuters) -Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug. The settlements with so-called direct purchasers, indirect purchasers and retailers require approval by…
